Helen Louise Collins

Insider Reports History

Entity
Individual
Location
Two Corporate Drive, South San Francisco, CA
Signature
/s/ Ben Hohl, by power of attorney
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Helen Louise Collins:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Enliven Therapeutics, Inc. CHIEF MEDICAL OFFICER Common Stock 0 $0 $30.00 Oct 18, 2024 Direct
Enliven Therapeutics, Inc. CHIEF MEDICAL OFFICER Stock Option (right to buy) 266K Oct 18, 2024 Direct
IO Biotech, Inc. Director Stock Option (Right to Buy) 45.6K Jun 6, 2024 Direct
Kura Oncology, Inc. Director Option to purchase common stock 26K Jun 5, 2024 Direct

Insider Reports Filed by Helen Louise Collins

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ELVN Enliven Therapeutics, Inc. Oct 18, 2024 3 -$22.5K 4 Oct 22, 2024 CHIEF MEDICAL OFFICER
IOBT IO Biotech, Inc. Jun 6, 2024 1 $0 4 Jun 7, 2024 Director
KURA Kura Oncology, Inc. Jun 5, 2024 1 $0 4 Jun 7, 2024 Director
ELVN Enliven Therapeutics, Inc. Apr 11, 2024 3 -$452K 4 Apr 15, 2024 CHIEF MEDICAL OFFICER
ELVN Enliven Therapeutics, Inc. Feb 13, 2024 1 $0 4 Feb 15, 2024 CHIEF MEDICAL OFFICER
IOBT IO Biotech, Inc. Nov 15, 2023 1 $0 4 Nov 17, 2023 Director
IOBT IO Biotech, Inc. Nov 9, 2023 0 $0 3 Nov 17, 2023 Director
KURA Kura Oncology, Inc. May 31, 2023 1 $0 4 Jun 2, 2023 Director
ELVN Enliven Therapeutics, Inc. Apr 4, 2023 1 $0 4 Apr 6, 2023 Chief Medical Officer
ELVN Enliven Therapeutics, Inc. Feb 23, 2023 1 $0 4 Feb 27, 2023 Chief Medical Officer
ELVN Enliven Therapeutics, Inc. Feb 23, 2023 0 $0 3 Feb 27, 2023 Director
KURA Kura Oncology, Inc. Jun 21, 2022 1 $0 4 Jun 23, 2022 Director
KURA Kura Oncology, Inc. Jul 28, 2021 2 $0 4 Jul 29, 2021 Director
KURA Kura Oncology, Inc. Jul 28, 2021 0 $0 3 Jul 29, 2021 Director